Top Qs
Timeline
Chat
Perspective
TM-38837
Chemical compound From Wikipedia, the free encyclopedia
Remove ads
TM-38837 is a small molecule inverse agonist/antagonist of the CB1 cannabinoid receptor, with peripheral selectivity. It is being developed for the treatment of obesity and metabolic disorders by 7TM Pharma.[1] The company has announced phase I clinical trials.
This article may rely excessively on sources too closely associated with the subject, potentially preventing the article from being verifiable and neutral. (April 2011) |
TM-38837 is among the first of a new generation of cannabinoid receptor antagonist designed to avoid the central nervous system liabilities of the first generation CB1 receptor antagonists such as rimonabant.[2]
Remove ads
See also
References
External links
Wikiwand - on
Seamless Wikipedia browsing. On steroids.
Remove ads